Expanded Access to Adagrasib (MRTX849) for Patients with Advanced Solid Tumors with KRAS G12C Mutation

Sponsor: Mirati Therapeutics Inc.

Expanded Access
Approved for Marketing
Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05162443

Provider View

This program offers access to the drug adagrasib (MRTX849) for patients with advanced solid tumors that have a specific genetic mutation called KRAS G12C, who have already received treatment and have limited options.

Patient Parameters

Program Overview

The purpose of this program is to provide access to the drug adagrasib (MRTX849) for patients with advanced solid tumors that have a KRAS G12C mutation. This is for patients who have already been treated but need more options because they cannot join a clinical trial or receive standard treatments.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of an advanced or metastatic solid tumor.
  • Have a confirmed KRAS G12C mutation in the tumor.
  • Cannot join a current clinical trial for MRTX849.
  • No other standard treatment options available or not eligible for them.
  • Have good organ function.
  • Can have cancer that has spread to the brain, under certain conditions.
  • Have an ECOG performance status of 2 or less, meaning they are able to carry out light work or are fully active.

Exclusion Criteria

  • Have a history of intestinal diseases or surgeries that affect digestion or the ability to swallow.
  • Have had previous treatments targeting the KRAS G12C mutation.
  • Have another active cancer.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.